Amyotrophic lateral sclerosis (ALS) is highly prevalent among young U.S. war veterans deployed post-9/11, particularly Air Force personnel, tactical operation officers, and health care workers, a recent study suggests. The findings suggest that there is an early onset of ALS among deployed military service members, the researchers said. Titled…

Aquestive Therapeutics has granted a development and commercialization license to Zambon Pharma for its investigational oral film formulation of riluzole as a treatment for amyotrophic lateral sclerosis (ALS) in the European Union (EU). Under the terms of the agreement, Zambon will be…

Small molecule inhibitors that block the activity of SARM1 — an enzyme that plays a key role in nerve cell degeneration — prevent the degeneration of axons in mice and cellular models of disease, a preclinical study has found. These findings may be the first steps towards the development…

The non-invasive delivery of ultrasound waves in a controlled, targeted manner can be safely used to open the blood-brain barrier in people with amyotrophic lateral sclerosis (ALS), giving temporary access to their motor cortex, results from a first-in-human trial show. The approach — called magnetic resonance guided…

Aural Analytics and the Translational Genomics Research Institute (TGen) will collaborate on a new acupuncture clinical trial to assess how the treatment affects speech in people recently diagnosed with amyotrophic lateral sclerosis (ALS). TGen, a nonprofit medical research institute, will sponsor…

Radicava (edaravone), an intravenous treatment for amyotrophic lateral sclerosis (ALS), is now commercially available in Canada, Mitsubishi Tanabe Pharma Canada (MTP-CA) has announced. The treatment was approved in Canada in October 2018, and has since been under the regulatory process that determines how, where, and at what…

Exercise appears to benefit people with amyotrophic lateral sclerosis (ALS) by normalizing molecular changes that occur at the junction of nerves and muscles, but by degrees that depend on the type of exercise, a study in a mouse model of ALS suggests. While running and swimming both lessened the profound molecular…

The Canadian Intellectual Property Office has approved a new patent application that will allow MediciNova to use its investigational therapy ibudilast (MN-166) for the treatment of patients with amyotrophic lateral sclerosis (ALS) in Canada. The patent covers a wide range of oral ibudilast doses in people…

AcuraStem has triggered $3 million in Phase 2 funding from its Small Business Innovation Research (SBIR) grant, which the biotechnology company will use to start the second stage of its AS-1 program. That patient-derived stem cell therapy program is aimed at…

Health professionals in Canada are more likely to recommend stretching than strength or aerobic exercises to people with amyotrophic lateral sclerosis (ALS), a recent survey found. However, this approach isn’t supported by currently available data. The survey results were published in the journal BMC Neurology in a study titled,…